Anthi Marina Markantonatou

Dr. Anthi Marina Markantonatou

AHEPA University Hospital, Thessaloníki, Kentrikí Makedonía, Greece

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
AMAnthi Marina Markantonatou
Anthi Marina Markantonatou
KSKonstantinos Samaras
Konstantinos Samaras
Timoleon-Achilleas VyzantiadisTimoleon-Achilleas Vyzantiadis
Timoleon-Achilleas Vyzantiadis
Microbes are found in the environment, possibly more often as biofilms than in planktonic forms. Biofilm formation has been described for several important fungal species. The presence of a dermatophytoma in a dermatophytic nail infection was the basis for the proposal that dermatophytes form biofilms as well. This could explain treatment failure and recurrent dermatophytic infections. Several investigators have performed in vitro and ex vivo experiments to study the formation of biofilms by dermatophytes and their properties. The nature of the biofilm structure itself contributes to fungal protection mechanisms against many harmful external agents, including antifungals. Thus, a different approach should be carried out regarding susceptibility testing and treatment. Concerning susceptibility testing, methods to evaluate either the inhibition of biofilm formation, or the ability to eradicate it, have been introduced. As for treatment, in addition to classical antifungal agents, some natural formulations, such as plant extracts or biosurfactants, and alternative approaches, such as photodynamic therapy, have been proposed. Studies that connect the results of the in vitro and ex vivo experimentation with clinical outcomes are required in order to verify the efficacy of these approaches in clinical practice.

1 May 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
AMAnthi Marina Markantonatou
Anthi Marina Markantonatou
ATHANASIOS TRAGIANNIDISATHANASIOS TRAGIANNIDIS
ATHANASIOS TRAGIANNIDIS
VGVasiliki Galani
Vasiliki Galani
DDDimitrios Doganis
Dimitrios Doganis
KAKondylia Antoniadi
Kondylia Antoniadi
Timoleon-Achilleas VyzantiadisTimoleon-Achilleas Vyzantiadis
Timoleon-Achilleas Vyzantiadis
An audit based on a specific questionnaire was attempted, in order to investigate the mycology laboratory diagnostic capacity for invasive fungal diseases (IFDs) in Greek Paediatric Haematology-Oncology departments/units. The study provided the relevant information for the years 2019 and 2020 and included data from all units, concerning culture-based methods and direct microscopy, phenotypic and molecular identification, sensitivity testing, serology and molecular diagnosis, as well as therapeutic drug monitoring. The target was mostly to reveal the level of laboratory coverage for hospitalised paediatric patients, independently of the possibility of performing the tests in the host hospital, or otherwise to refer the specimens elsewhere. In total, the current study demonstrated that the most important facilities and services regarding the IFD diagnostics for paediatric haematology-oncology patients in Greece are available and relatively easily accessible, with a reasonable turnaround time. Acting as an initial registry for further improvements, the audit can serve as a valuable approach to the actual situation and future perspectives. A national clinical mycology network under the auspices of the relevant scientific societies will probably facilitate collaboration between all the departments (clinical and laboratory) involved in invasive fungal infections and provide an easier approach to any necessary test for any hospitalised patient.